NEXGEL sees large market opportunity with its hydrogel patch to treat amblyopia

NEXGEL (NASDAQ:NXGL) CEO Adam Levy joined Proactive's Stephen Gunnion with details of a new hydrogel eye patch the company has developed to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both. Levy says amblyopia is present in 2% to 4% of the American population, creating a large opportunity for NEXGEL. The patches are gentle, can be worn for long periods of time without experiencing any pain or discomfort and are suitable for children, he says. He also discusses positive results from a proof-of-concept study on diclofenac hydrogel patches designed to treat pain caused by arthritis, joint pain, muscle aches and more.